A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Filters
Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health
2018
Pharmacological Reviews
Preserved Fulltext
The three-dimensional protein structural view of personal mutanomes sheds light on the functional consequences of clinically actionable mutations revealed in tumor diagnosis and followed up in personalized ...
In this review, we describe the protein structural landscape of personal mutanomes and provide expert opinions on rational strategies for more streamlined oncological drug discovery and molecularly targeted ...
Wang and colleagues examined RNA-seq data from 37 patients with chronic lymphocytic leukemia and found that SF3B1 mutations increased the telomerase activity, Notch signaling, and DNA damage, by promoting ...
doi:10.1124/pr.118.016253
pmid:30545954
pmcid:PMC6294046
fatcat:njxfrnuje5fyzdtajf7aakuslu
Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia
2013
Proceedings of the National Academy of Sciences of the United States of America
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf.
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults in the Western hemisphere. ...
phosphatase PP1-beta catalytic subunit | B-lymphoid malignancy B -cell chronic lymphocytic leukemia (B-CLL) is the most common form of leukemia in adults in Western countries (1). ...
The authors declare no conflict of interest. This article is a PNAS Direct Submission. ...
doi:10.1073/pnas.1214326110
pmid:23382248
pmcid:PMC3581970
fatcat:wqvolyvwdbc73kcacjxehaatw4
JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
2018
F1000Research
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
Despite a weak effect on the cause of the disease itself in MPNs, it improves the clinical state of patients and increases survival in myelofibrosis. ...
JAK inhibitors have been developed following the discovery of the V617F JAK2 in 2005 as the driver mutation of the majority of non-BCR-ABL1 myeloproliferative neoplasms (MPNs). ...
This occurs in several types of lymphoma as well as in chronic lymphocytic leukemia and Waldenström macroglobulinemia 58 . ...
doi:10.12688/f1000research.13167.1
pmid:29399328
pmcid:PMC5773931
fatcat:2536ogr5lvemxlhnyfe2cgczqa
The Human Proteome Organization Chromosome 6 Consortium: Integrating chromosome-centric and biology/disease driven strategies
2014
Journal of Proteomics
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Chromosome 6 (Ch6) provides an excellent model for integration of these two tasks. This metacentric chromosome has a complement of 1002-1034 genes that code for known, novel or putative proteins. ...
Ch6 is functionally associated with more than 120 major human diseases, many with high population prevalence, devastating clinical impact and profound societal consequences. ...
Deletions in 6q21 occur in 7% of B-cell chronic lymphocytic leukemias (B-CLL) [25] and of 6q27 in 21% of patients with CLL, while deletions in the long arm of chromosome 6 are related to diffuse B-cell ...
doi:10.1016/j.jprot.2013.08.001
pmid:23933161
pmcid:PMC4096956
fatcat:ph5iovegmrdgjfhkohvemoyr7i
A Systematic Review on the Contribution of Artificial Intelligence in the Development of Medicines for COVID-2019
2021
Journal of Personalized Medicine
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
Among other, the selected studies on new treatments against COVID-2019 were classified, as follows: studies with in-vitro and/or clinical data; association of known drugs; and other studies related to ...
repurposing of drugs. ...
Conflicts of Interest: The author declares no conflict of interest. ...
doi:10.3390/jpm11090926
pmid:34575703
fatcat:ldgzoqcddbgmziegmvaujucr2i
Recurrent Rearrangements in Prostate Cancer: Causes and Therapeutic Potential
2013
Current Drug Targets
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf.
of prostate cancer patients. ...
However, gene fusions as driver mutations in cancer have classically been a distinction in leukemia and other rare instances until recently with the discovery of gene fusion events occurring in 50 to 75% ...
The classical example of gene rearrangements is the Philadelphia chromosome found in chronic myelogenous leukemia (CML) consisting of the translocation of chromosome 9 and 22 creating BCR-ABL, an activated ...
doi:10.2174/1389450111314040006
pmid:23410129
pmcid:PMC3733264
fatcat:yrb6yalwnjbk7ookvvfav3r3ee
Potential mechanisms of resistance to venetoclax and strategies to circumvent it
2017
BMC Cancer
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf.
Venetoclax (ABT-199), a first-in-class orally bioavailable BCL-2-selective inhibitor, was recently approved by the FDA for use in patients with 17p-deleted chronic lymphocytic leukemia who have received ...
It is also being evaluated in numerous clinical trials for treating patients with various hematologic malignancies. ...
Acknowledgements We thank past and present members of the BCL-2 project team for helpful discussions. ...
doi:10.1186/s12885-017-3383-5
pmid:28578655
pmcid:PMC5457565
fatcat:5ugecue4dvgsbedemptflxjuhe
CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents
2021
Frontiers in Oncology
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
This therapeutic potential has been utilized for the discovery of CDK9 inhibitors, some of which have entered human clinical trials. ...
in preclinical and clinical settings. ...
Stereo ribbon plot of the 3D structure of CDK9-cyclin T1 in complex with ATP (Protein data bank: 3BLQ). ...
doi:10.3389/fonc.2021.678559
pmid:34041038
pmcid:PMC8143439
fatcat:ebsnc2h22baarhl63uvfefthou
Exploiting drug-disease relationships for computational drug repositioning
2011
Briefings in Bioinformatics
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf.
initiates from the clinical perspective of disease or its pathology. ...
Finding new uses for existing drugs, or drug repositioning, has been used as a strategy for decades to get drugs to more patients. ...
lymphocytic leukemia and rheumatoid arthritis). ...
doi:10.1093/bib/bbr013
pmid:21690101
pmcid:PMC3137933
fatcat:pcwnzy26ezg2rgymbyvgw3cjsq
In silico Molecular Docking Analysis of Imatinib to Target the Marker Proteins of Breast Cancer
2021
Current Journal of Applied Science and Technology
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf.
The study helped to evaluate the pharmacokinetic properties and binding efficiency of Imatinib towards the breast cancer proteins. ...
The results of study showed that the Imatinib exhibited better binding affinities to mTOR and HER2 as compared to ER, PARP and P53 proteins. ...
Imatinib (Gleevec ® or Glivec ® ) is also known as a magical bullet developed by Nicholas Lyndon, a biochemist of Ciba-Geigy and the clinical trial was conducted with the patients of chronic myeloid leukemia ...
doi:10.9734/cjast/2021/v40i3631579
fatcat:tqgffrh3wndkzclmyylh22p6ya
Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside
2021
Clinical Epigenetics
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
The study of epigenetic biomarkers has led to the identification of numerous drugs with an increasingly significant role in clinical therapy especially of cancer patients. ...
Here, we provide an overview of clinical epigenetics within the context of network analysis. ...
NM applications may improve our mechanistic understanding of tumorigenesis and the dynamics of driver and contributing (epi)mutations within the 3D structure of the cell and of tissues. ...
doi:10.1186/s13148-021-01047-z
pmid:33785068
pmcid:PMC8010949
fatcat:vojcp6avfrdfzi2vero5iaznji
Breakpoint Analysis of Transcriptional and Genomic Profiles Uncovers Novel Gene Fusions Spanning Multiple Human Cancer Types
2013
PLoS Genetics
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf.
Gene fusions, like BCR/ABL1 in chronic myelogenous leukemia, have long been recognized in hematologic and mesenchymal malignancies. ...
Taken together, we provide a robust approach for gene fusion discovery, and our results highlight a more widespread role of fusion genes in cancer pathogenesis. ...
Acknowledgments The authors would like to thank the members of the Pollack lab for helpful discussion.
Author Contributions ...
doi:10.1371/journal.pgen.1003464
pmid:23637631
pmcid:PMC3636093
fatcat:yi3eyariwfh5xgdsm7ts6mdby4
From Nanoparticles to Cancer Nanomedicine: Old Problems with New Solutions
2021
Nanomaterials
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf.
for cancer patients. ...
Anticancer nanomedicines have been studied over 30 years, but fewer than 10 formulations have been approved for clinical therapy today. ...
Conflicts of Interest: The authors declare no conflict of interest. ...
doi:10.3390/nano11071727
doaj:4868138b586a4a2db013e70594640c53
fatcat:pzig2ckbd5b67dkx6gqnyf7iru
Tumor microenvironment and cancer therapy resistance
2016
Cancer Letters
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf.
In the long run, continued inputs into translational medicine remain highly desired to achieve durable responses in the current era of personalized clinical oncology. ...
Innate resistance to various therapeutic interventions is a hallmark of cancer. ...
Acknowledgements The author sincerely apologizes for not being able to thoroughly cite the contribution of all studies related to the current topic due to space restriction, and gratefully ...
doi:10.1016/j.canlet.2015.07.044
pmid:26272180
fatcat:5o3k4jo325adpfrt2udnhmsyvq
Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells
2020
Frontiers in Immunology
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
The feasibility and safety of such approaches is currently tested in clinical trials. ...
which are ever more commonly introduced into cancer patient treatment protocols. ...
to Alemtuzumab (Campath R ), which is an antibody used to eliminate CD52 + lymphocytes in B-cell chronic lymphocytic leukemia (66) . ...
doi:10.3389/fimmu.2020.01965
pmid:32903482
pmcid:PMC7438733
fatcat:e4pwswh3krcqthzdnei6y3ymza
« Previous
Showing results 1 — 15 out of 954 results